Albert Charron, MD
Family Medicine · Nokomis, FLNPI 1437158409
Payments from drug & device makers
Across 644 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$2K
- Pfizer$1K
- Novo Nordisk$861
- Amgen$853
- GSK$727
- plus $3K from 32 others
What the payments were for
- Food & beverage$11,087100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 147 | $2,391 |
| Lilly USA, LLC | 97 | $1,633 |
| Pfizer | 66 | $1,245 |
| Novo Nordisk | 46 | $861 |
| Amgen | 55 | $853 |
| GSK | 67 | $727 |
| AstraZeneca | 24 | $640 |
| Exact Sciences | 16 | $438 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $343 |
| Astellas Pharma US Inc | 18 | $304 |
| Bayer | 13 | $275 |
| Boehringer Ingelheim | 10 | $181 |
| Merck | 9 | $157 |
| Radius Health, Inc. | 5 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $82 |
| Abbott | 4 | $77 |
| Amarin Pharma, Inc. | 4 | $73 |
| Biohaven Pharmaceuticals, Inc. | 3 | $67 |
| Almatica Pharma LLC | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Dexcom, Inc. | 3 | $60 |
| Sumitomo Pharma America, Inc. | 3 | $56 |
| Optinose US, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Novartis | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Smith+Nephew | 2 | $35 |
| Johnson & Johnson | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Genentech USA, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Cala Health, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,110 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 110 | $143,284 |
| EliquisApixaban | 117 | $138,640 |
| OzempicSemaglutide | 57 | $111,959 |
| JardianceEmpagliflozin | 73 | $110,007 |
| FarxigaDapagliflozin Propanediol | 60 | $80,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $77,131 |
| Repatha SureclickEvolocumab | 38 | $53,528 |
| ProliaDenosumab | 20 | $34,997 |
| XareltoRivaroxaban | 34 | $33,177 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $26,658 |
| TrulicityDulaglutide | 15 | $26,113 |
| JanuviaSitagliptin Phosphate | 12 | $19,681 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $17,595 |
| LinzessLinaclotide | 25 | $15,670 |
| Spiriva RespimatTiotropium Bromide | 11 | $9,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,633 | $169,397125 claims |
| PfizerEliquis, Premarin | $1,245 | $145,393129 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $181 | $136,812103 claims |
| Novo NordiskOzempic | $861 | $111,95957 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $727 | $103,78981 claims |
| AstraZenecaFarxiga | $640 | $80,01560 claims |
| AmgenProlia | $853 | $34,99720 claims |
| Johnson & JohnsonXarelto | $30 | $33,17734 claims |
| MerckJanuvia | $157 | $19,68112 claims |
| AbbVieLinzess, Synthroid | $2,391 | $19,30663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Nokomis
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.